Body image is part physical and part mental. If weight loss alone isn't helping, strategies from body image psychology can ...

But behind the headlines and hashtags lies a disturbing trend that deserves urgent attention: the rise of compounded GLP-1s ...

Shares in Omada Health (NASDAQ:OMDA) rose 21% in their Nasdaq debut on Friday, closing at US$23 after pricing at US$19 in the ...

Weight-loss injections are taking off in Switzerland. But despite obesity being more prevalent among men, it is women who are ...

Fresh from a $150 million IPO on Wall Street, Omada Health CEO Sean Duffy shares his thoughts on speed bumps, GLP-1s, staying ...

After reviewing several large epidemiological studies, clinical trial and in-market data, EMA’s Pharmacovigilance Risk Assessment Committee has concluded non-anterior ischemic optic neuropathy is a ...

Omada Health went public on the Nasdaq Friday, marking the second digital health company to do so after a post-pandemic ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

Omada Health (NASDAQ:OMDA) opened its first day of trading with a bangjumping 21% to $23 after pricing its IPO at $19. That ...

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

Omada Health is making its public-market debut, propelled by Americans’ renewed focus on how weight affects physical health.